Palisade Bio, Inc. (PALI)
| Market Cap | 196.93M -11.9% |
| Revenue (ttm) | 500,000 |
| Net Income | -31.94M |
| EPS | -0.20 |
| Shares Out | 174.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,032,623 |
| Open | 1.140 |
| Previous Close | 1.160 |
| Day's Range | 1.100 - 1.180 |
| 52-Week Range | 1.080 - 2.855 |
| Beta | 1.62 |
| Analysts | Strong Buy |
| Price Target | 9.80 (+767.26%) |
| Est. Earnings | Nov 20, 2026 |
About PALI
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and co... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for PALI stock is "Strong Buy." The 12-month stock price target is $9.8, which is an increase of 767.26% from the latest price.
News
Palisade Bio doses first patient in ASCENTRA-UC trial
Palisade Bio (PALI) announced that the first patient has been dosed in ASCENTRA-UC, its global Phase 2b clinical trial evaluating PALI-2108 in approximately 204 patients with moderately to severely ac...
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability
Palisade Bio presents clinical, translational findings at UEG
Palisade Bio (PALI) announced clinical and translational findings presented in one oral presentation and three moderated posters at United European Gastroenterology, or UEG, Week 2026, held October 17...
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
Five-patient Phase 1b Crohn's disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days
Palisade Bio initiated with an Outperform at Raymond James
Raymond James analyst Thomas Deal initiated coverage of Palisade Bio (PALI) with an Outperform rating and $6 price target Palisade is developing PALI-2108 for inflammatory bowel disease, including ulc...
Palisade Bio to present clinical, translational data for PALI-2108 at UEG Week
Palisade Bio (PALI) announced that its lead program, PALI-2108, will be featured in four presentations at United European Gastroenterology, UEG, Week 2026. The presentations include an oral presentati...
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026
Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn's disease
Palisade Bio Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
PALI-2108, a targeted oral PDE4 inhibitor, is advancing through phase II trials for ulcerative colitis and Crohn's disease after promising phase I safety and efficacy signals. Enrollment is progressing ahead of schedule, with strong financial resources supporting milestones through 2028.
Palisade Bio expands Phase 2b Ascentra-UC with Health Canada CTA clearance
Palisade Bio (PALI) announced that Health Canada has cleared the Company’s Clinical Trial Application, CTA, for Ascentra-UC, its global Phase 2 study evaluating PALI-2108 in patients with moderately t...
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active ...
Palisade Bio receives FDA clearance of IND for PALI-2108
Palisade Bio (PALI) announced that the U.S. Food and Drug Administration, FDA, has cleared the Company’s Investigational New Drug, IND, application for PALI-2108, enabling initiation of the Phase 2 AS...
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD
ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn's disease First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targe...
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Presentation scheduled for September 23, 2026 at 1:00 PM ET Access the webcast here Denver, CO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a cl...
Palisade Bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A novel PDE4 inhibitor for IBD, designed for local delivery and improved tolerability, is advancing through phase IIb trials in ulcerative colitis and preparing for Crohn's disease studies. The drug shows promising biomarker and efficacy data, with key updates and data presentations expected over the next year.
Palisade Bio Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
PALI-2108, a gut-targeted oral PDE4 inhibitor, is advancing to phase II trials in both UC and Crohn's, with strong early efficacy and safety signals. The company is well-funded to complete these studies, aiming for aggressive enrollment and interim data updates.
Palisade Bio to Participate in Upcoming Investor Conferences
Denver, CO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patie...
Palisade Bio reports Q2 EPS (22c), consensus (5c)
“The team at Perspective is highly energized as we continue to build on the significant clinical progress we’re making across our pipeline, prepare for our first Phase 3 study, and…
Palisade Bio Quarterly report: Q2 2026
Palisade Bio has published its Q2 2026 quarterly earnings report on August 10, 2026.
Palisade Bio Earnings release: Q2 2026
Palisade Bio released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Palisade Bio Slides: Corporate presentation
Palisade Bio has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Palisade Bio initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Palisade Bio (PALI) with an Outperform rating and $8 price target The firm believes Palisade Bio offers investors an attractive way to participate in the large/growin...
Palisade Bio management to meet with Piper Sandler
Meeting to be held in Boston on July 14 hosted by Piper Sandler.
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage b...
Palisade Bio receives FDA clearance to start ulcerative colitis study
Palisade Bio (PALI) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for its oral drug candidate, PALI-2108. The clearance allows the company t...
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe